We have investigated the basis of androgen resistance in seven unrelated individuals with complete testicular feminization or Reifenstein syndrome caused by single amino acid substitutions in the hormone-binding domain of the androgen receptor. Monolayer-binding assays of cultured genital skin fibroblasts demonstrated absent ligand binding, qualitative abnormalities of androgen binding, or a decreased amount of qualitatively normal receptor.
Introduction
The syndromes caused by mutations in the androgen receptor gene encompass a spectrum of phenotypic abnormalities ranging from phenotypic women with the syndrome of complete testicular feminization to men with minor defects of virilization or infertility. Monolayer-binding assays of [3H]dihydrotestosterone binding in genital skin fibroblasts cultured from affected subjects have defined four categories of defective re-ceptors: absent androgen binding, normal androgen binding, qualitative abnormalities of androgen binding, and reduced androgen binding (1) . The isolation of cDNAs encoding the androgen receptor and the definition of its genomic structure have allowed the characterization of the molecular defects responsible for androgen resistance in all four categories.
The largest number (approximately two-thirds) of androgen receptor abnormalities characterized to date are caused by mutations that result in amino acid substitutions in the protein. These mutations cause the replacement of amino acid residues in the DNA-or hormone-binding domain of the androgen receptor. In contrast to the other types of androgen receptor defects (gene deletions, termination codons, and abnormalities of mRNA splicing), which nearly always give rise to complete testicular feminization, amino acid substitutions can cause phenotypes that encompass the entire spectrum of androgen resistance.
In the present report, we investigated the basis of androgen resistance of seven patients in whom androgen resistance is caused by amino acid substitutions in the hormone-binding domain. One was characterized by the absent androgen binding, five by qualitative abnormalities of androgen binding, and one by a reduced level of qualitatively normal androgen binding.
Methods
Cell cultures. Primary cultures of genital skin from patients N-69, Q-571, and Q-851 were established as previously described (2) and maintained in MEM with 10% FCS and 1% penicillin and streptomycin. CHO and CVl cells were obtained from the American Type Culture Collection (Rockville, MD) and were maintained as previously described (3) .
Monolayer-binding analysis. Monolayer-binding analysis in cultured fibroblasts or transfected cells was performed as previously described (4) . Briefly, monolayer cultures were incubated with medium containing different concentrations of 3H-labeled dihydrotestosterone (DHT)1 in the presence or absence of a 500-fold excess of unlabeled ligand. After incubation for 1 h at 370C the culture was rinsed, harvested, and assayed for protein and tritiated steroid content. Thermolability was assessed by incubating monolayer cultures with saturating concentration of ligand at 370C and 41'C for 1 h. A reduction in specific androgen binding at 41'C compared to 370C of greater than 40% is defined as thermolabile. After incubation, the cells were harvested and processed as above (4) . The rate of ligand dissociation was examined by incubating parallel cultures with 2 nM [3H]mibolerone for 1 h at 370C in the presence or absence of excess unlabeled mibolerone. At time 0 the medium containing the radioactive ligand was removed and replaced with medium containing 2 nM cold mibolerone, and the incubation was continued for 5 h. The percentage of specific mibolerone binding remaining at hourly intervals was then compared to the level of specific mibolerone binding in samples to which no competitor steroid had been added (4) . The dissociation rate is considered normal if > 60% of the specific androgen binding remains after 3 h.
Immunoblot analysis. Immunoblot analysis of genital skin fibroblasts and of transfected eukaryotic cells was performed as described elsewhere (5) using polyclonal antipeptide antibodies (U402) directed at the first 21 amino acid residues of the amino terminus of the androgen receptor protein.
Site-directed mutagenesis. The mutations detected in patients Q-851, N-69, Q-48, Q-593, Q-691, and R-855 were inserted into an androgen receptor cDNA expression vector as previously described (6, 7) . Briefly, two oligonucleotides containing the detected mutations and directed 5 '-3 '(S) or 3 '-5 '(AS) were synthesized and used with oligonucleotides MutH3 and 710-Xba to amplify the portion of androgen receptor cDNA located between the internal HindIII site and an XbaI site located just 3' of the coding sequence. The final product of the reaction, which contains a HindIll restriction endonuclease cleavage site at the 5' terminus and an XbaI restriction site at the 3' terminus was ligated into an expression plasmid driven by the cytomegalovirus promoter. The expression plasmid contains androgen receptor cDNA, from which the region between the internal HindH1 site and the XbaI site located 3' of the coding sequence had been deleted. The insertion of the correct sequence was confirmed by nucleotide sequence analysis of the resulting plasmids.
Cell culture and transfection. The CV1 cells and CHO cells used for transfection studies of mutants and wild-type androgen receptors do not express endogenous androgen receptor. CHO cells are deficient in androgen metabolizing enzymes while CV1 cells actively metabolize androgen (8) .
Transfection experiments were performed by the calcium phosphate precipitation method (9) . CV1 cells were transiently transfected with plasmids encoding normal or mutant androgen receptors (200 ng), the reporter plasmid MMTV-luciferase (10 ,ug), and a control plasmid, CMV-,6-galactosidase (1 pg). After transfection, the cells were incubated in medium containing 5% charcoal stripped serum and saturating concentrations of DHT (2 nM) for 48 h. After 48 h, the cell cultures were harvested and assayed for /3-galactosidase and luciferase (10) activity. In these experiments, luciferase activity reflects the transcriptional activity of the different androgen receptors, and l3-galactosidase activity is used to correct for the efficiency of transfection.
Experiments examining the transcriptional activity exerted by the normal androgen receptor (CMV3. 1 ) and the 851 mutation (CMV85 1 ) in the presence of different ligands were performed by transfecting CV1 cells as described above and by using saturating concentrations of testosterone, DHT, or mibolerone for 48 h after transfection. Experiments examining the effect of supraphysiologic concentration of DHT on the transcriptional activity exerted by the normal androgen receptor and mutants Q-571 and Q-851 were performed by transient transfection of CV1 cells with the above plasmids and by stimulation for 48 h after transfection with 2 or 20 nM of DHT.
CHO cells were used in stable transfection experiments to examine the effects of mutations on the ligand-binding properties of the receptor. In these experiments, cDNAs encoding normal or mutant androgen receptors were cotransfected with the plasmid psV2neo ( 11). After selection with medium containing 400 ,g/ml of active G418 pools of cells (-50-200 independent colonies) were used in monolayer-binding experiments.
Results
Clinical background and clinical history. The subjects investigated in this study were affected by complete testicular feminization (N-69, Q-571, Q-851, R-855) (12) . The values included in Table I reflect the results of more recent binding analyses. The reason for these differences is not clear, but may reflect subtle methodologic changes.
Immunoblot analysis of genital skin fibroblasts. To determine whether absent or reduced levels of specific androgen binding in fibroblast cultures is due to the expression of a defective form of androgen receptor or alteration in the level of androgen receptor expression, the level of androgen receptor protein expression was estimated by immunoblot analysis in cultured genital skin fibroblasts (5) (Fig. 1) . Strain N-69 produces immunoreactive androgen receptor protein that is indistinguishable in size or amount from the 1 I0-kD androgen receptor protein doublet produced by control fibroblasts (strain 704, Fig.  1 ). Thus, there is a striking contrast between the results of ligand-binding assays and immunoblot analyses of genital skin fibroblasts of patient N-69. As expected from the monolayerbinding data, fibroblast cultures from patients Q-571 and Q-851 ( Fig. 1 ) also produce immunoreactive 1 10 kD androgen receptor protein. Similar levels of immunoreactive 110 kD androgen receptor were detected for patients Q-593, Q-691, and R-855 (data not shown).
Sequence analysis of mutant androgen receptors. Southern analysis of genomic DNA from all seven patients indicated that, in each, the coding segments of the androgen receptor gene is present and grossly intact (reference 7, data not shown). We have reported previously ( 12) the identification of single nucleotide substitutions in the androgen receptor gene from each patient that result in the replacement of single amino acid residues within the hormone-binding domain of the receptor protein (Table I) . Notably, the amino acid substitutions predicted for mutants N-69, Q-57 1, Q-48, and Q-851 are localized in a cluster of mutations within the amino terminus of the hormone-binding domain, while the substitutions predicted for the Q-593, Q-691, and R-855 mutant receptors are within the carboxy terminus cluster of mutations. The remaining portion of the androgen receptor open-reading frame that was sequenced was identical in each case except for minor differences in the length of the polymorphic glutamine homopolymeric segment comprising amino acids 58-78. The glycine homopolymeric segment (amino acids 448-470) was not sequenced.
Monolayer-binding analysis of stably transfected CHO cells. The metabolism of androgens is rapid in fibroblasts and in many cell lines. For this reason, studies of the kinetics of ligand association and dissociation usually require the use of substituted, nonmetabolizable androgens. The stable expression of the mutant receptors in CHO cells (which are relatively deficient in steroid-metabolizing enzymes; reference 8) permits comparison of the binding of a variety of steroids to the mutant receptors under conditions in which steroid metabolism is negligible (Table II) .
As expected, substantial levels of specific DHT binding were detected in cells expressing the androgen receptors predicted for patients Q-691, Q-851, R-855, Q-593, and Q-48. As expected from the fibroblast binding assays, the receptors predicted for three of these five patients are qualitatively abnormal as demonstrated by analysis of the rate of dissociation of ligand from the receptor.
In agreement with the results of binding assays performed Q-851I) fibroblast strains. Cells were harvested, solubilized, and electrophoresed on a 7.5% SDS-polyacrylamide gel, transferred to nitrocellulose and probed with an antibody (U402) directed at the amino terminus of the receptor protein (5) . The number of cells applied is shown in parentheses. Table II , the 571 receptor is able to bind 5a-DHT and mibolerone but unable to bind testosterone when assayed in whole cell monolayer binding assays. Interestingly, although the 571 mutant androgen receptor can bind mibolerone, this ligand rapidly dissociates from the receptor, raising the possibility that the lack of binding observed using labeled testosterone might be due to extreme instability of the 571 androgen receptor-testosterone complex in the monolayer-binding assay. To address this possibility, we examined the ability of unlabeled androgens ( Binding assays were performed on pools of G418-resistant cells transfected with the indicated expression plasmids. Thermolability and dissociation rates were measured and classified as described in the text. Thermolability is defined as greater than a 40% decline in androgen binding when performed at 41°C compared to parallel results performed at 37°C. A dissociation rate is considered normal when greater than 60% of the specific androgen binding remains at 3 h. N/A, not applicable; T, testosterone; Mb, mibolerone.
(F762L). As shown in
(mutant Q-48) of that observed for the normal androgen receptor.
The substantial level of functional activity in functional assays observed for several of the mutants (e.g., patients Q-48, Q-691, and Q-855) prompted us to examine whether a defect in the capacity of less potent androgens such as testosterone might correlate better with the phenotypic abnormalities observed in the patients. As shown in Table III , incubation of cells transfected with a cDNA encoding the normal androgen receptor with a saturating concentration of testosterone induces the MMTV-luciferase reporter gene to a level that is similar to that attained with DHT, in line with previous observations (8) . By contrast, only the mutant receptor for patient Q-691 showed comparable levels of activity following stimulation with DHT or testosterone. The differential response to DHT and testosterone stimulation was most pronounced in mutant Q-48 (77 vs. 18% of the activity observed for the normal androgen receptor stimulated with DHT).
Equally striking were the results obtained after stimulation of the transfected cells with the potent androgen mibolerone. In contrast to the results obtained with testosterone and DHT, a substantial induction of luciferase activity was observed for all but one of the mutant receptors (N-69), including several that would be predicted to be markedly defective in functional assays on the basis of patient phenotype. In fact, stimulation with mibolerone resulted in induction of the luciferase activity by several mutant androgen receptors (e.g., Q-48, Q-851, and R-593) to levels approaching that observed for the normal androgen receptor assayed in parallel. Only the N-69 mutant was unable to respond in the functional assay, and this receptor was also unable to bind testosterone, DHT, or mibolerone in monolayer-binding assays (Table I) .
The activation of the MMTV-luciferase reporter by the mutant receptors is partially restored by increased concentrations or frequent additions of dihydrotestosterone. Since the mutant receptor produced in Q-851 fibroblasts shows an increased rate of ligand dissociation, we investigated whether a partial or complete restoration of transcriptional activity would result from incubating CV1 cells expressing the Q-851 androgen receptor with a supraphysiologic concentration of ligand (20 nM) or by increasing the frequency of hormone addition. As shown in Table IV These results suggested that a shortened half-life of the hormone receptor complexes might underlie the abnormalities of the mutant receptors and might account for the changes in mutant androgen receptor function in response to enhanced hor-
Discussion
In the subjects examined to date, amino acid substitutions in the hormone-binding domain of the androgen receptor are the most common mutations causing androgen resistance and have been detected in individuals with a variety of phenotypes, including complete testicular feminization and Reifenstein syndrome. How these diverse ligand-binding domain mutations cause the different androgen resistant phenotypes has not been determined.
The current report attempts to address this issue. The seven subjects reported in these studies were chosen to encompass a range of abnormalities of androgen binding in genital skin fibroblast cultures caused by amino acid substitutions in the hormone-binding domain of the androgen receptor. Furthermore, the mutations analyzed were chosen to be representative of substitutions within the two regions most frequently affected by amino acid substitutions within the hormone-binding domain.
The results of these studies permit two types of conclusions to be drawn. The first pertains to the relationship between the nature of the amino acid substitutions in the hormone-binding domain of the androgen receptor and observed effects of ligand binding. The second is more general and explores the physiologic ramifications of these observations. Of the mutant receptors examined in this study, the receptor predicted for patient N-69 (W739R) is the most abnormal. This receptor protein does not bind testosterone, DHT, or mibolerone and is inactive in functional studies. These findings indicate that the alteration of the structure of the hormone-binding domain caused by the W739R amino acid substitution is such that the receptor is completely unable to bind androgen. This suggests that the re- The results of four separate experiments are presented. For each experiment, cells were transfected, stimulated, and assayed in parallel. Each value presented for each experiment is derived from the mean of three separate transfections assayed in the absence and presence of hormone. When stably expressed in CHO cells, the mutant androgen receptor predicted for patient Q-851 (P764S) behaves in a fashion similar to the androgen binding detected in cultured genital skin fibroblasts from this subject: the receptor displays normal affinity for androgen, and the only abnormality of binding detected is the rapid dissociation of ligand. It is interesting that a single amino acid replacement results in the phenotype of complete testicular feminization when the abnormally rapid dissociation of ligand from the receptor is the only receptor defect detected in fibroblasts or transfected CHO cells. Despite these subtle alterations of ligand binding, a substantial defect in receptor function is evident when the Q-851 receptor is analyzed in CV1 cells following stimulation with single doses of testosterone or DHT. Consistent with a defect of hormone receptor stability, the functional defect is partially or completely corrected after incubation with a saturating concentration of mibolerone or with repeated additions of DHT.
The androgen receptor predicted for Q-48 also displays an increased rate of ligand dissociation when assayed in fibroblast cultures or in transfected CHO cells. The mutation (A746D) is localized to a position 18 amino acids from the amino acid substitution responsible for the rapid ligand dissociation observed for patient Q-851 (P764S). The Q-571 mutation contains an amino acid replacement in this same region of the androgen receptor (F762L) and also demonstrates a rapid dissociation Androgen Receptor Hormone-binding Mutations Finally, the relationship between the genetic mutation identified in the androgen receptor gene and the phenotype observed in the patient is certain to be complex. At a minimum, attempts to explore this relationship must examine the changes in the level of androgen receptor expression and the residual function of the receptor caused by the androgen receptor mutation. In this respect, mutant androgen receptors that completely lack the ability to activate androgen-responsive reporter genes are associated with complete testicular feminization, but the partial forms of androgen resistance, such as Reifenstein syndrome, are less well understood. Our study suggests that the results of such experiments may in large part be dependent on the types of assays that are employed to assess the activity of the mutant androgen receptors in transfected cells. In the current study, we show that if a potent nonmetabolizable androgen such as mibolerone is used, a relationship between receptor function and phenotype is difficult to discern. By contrast, if single additions of physiologic ligands are employed instead (testosterone or DHT), the pattern of activity observed appears to have a more direct relationship to phenotype, although this relationship is not precise (see, for example, the results obtained in functional studies of the mutant androgen receptor predicted for patient R-691).
